SUMMARY Background
Loss of response to anti-tumour necrosis factor (TNF) therapy in patients with inflammatory bowel disease (IBD) is often caused by anti-drug antibody formation with neutralisation of drug effect. Addition of an immunomodulator has been suggested to reduce immunogenicity, leading to regained response.
Aim
To investigate whether addition of an immunomodulator to anti-TNF monotherapy could lead to anti-drug antibody suppression and regained clinical response in IBD patients.
Methods
We retrospectively collected measurements of infliximab or adalimumab serum concentrations and anti-drug antibodies to identify anti-drug positive patients with loss response who were given an immunomodulator.
Results
Anti-drug antibodies against infliximab and adalimumab were detected in 98/ 376 (26%) and in 61/226 (27%) patients, respectively. Immunomodulators were given to 17/159 patients. Clinical response was recaptured in 6/10 patients receiving a thiopurine and in all (7/7) patients receiving methotrexate. In 7/8 patients on infliximab, serum concentrations increased (median 2.84 lg/mL; IQR: 1.19-4.98) and in 6/9 patients on adalimumab (median 3.10 lg/mL; IQR: 1.45-4.45). This was accompanied by a decrease in anti-drug antibodies to undetectable levels (median 11 months for both anti-TNF agents). In 23 patients, no immunomodulator was added but anti-TNF interval was shortened (17/23) or dosage was increased (6/23), which resulted in a clinical response in 10/17 and 2/6 patients, respectively.
Conclusion
In 77% of IBD patients with loss of response due to immunogenicity, addition of immunomodulator resulted in undetectable anti-drug antibody levels, increased serum drug concentrations and regained clinical response. This strategy should be considered in this patient population before switching to other agents. INTRODUCTION Anti-tumour necrosis factor (TNF) antibodies such as infliximab (IFX) and adalimumab (ADL), are effective therapeutic agents to treat inflammatory bowel disease (IBD). [1] [2] [3] [4] However, a proportion of patients loses response over time, a phenomenon which is known as secondary loss of response. 5, 6 An important mechanism is the development of anti-drug antibodies due to a commonly observed immune response with therapeutic antibodies. Anti-drug antibodies can form complexes with the monoclonals and thereby neutralising their therapeutic effect. [7] [8] [9] Risk factors associated with immunogenicity include episodic treatment, low serum drug concentrations, anti-TNF monotherapy rather than combination with immunosuppressives and possibly the Human Leukozytenantigen genotype. [10] [11] [12] [13] Since therapeutic options for patients losing response to TNF inhibitors are limited, strategies to maximise drug effects are essential and reduction in immunogenicity is one of the strategies to achieve this goal. Maintaining adequate serum concentrations of anti-TNF antibodies is associated with clinical response in IBD patients. [14] [15] [16] [17] Formation of anti-drug antibodies results in enhanced clearance of the monoclonals and hence decreased serum concentrations. 18 The superiority of anti-TNF therapy in combination with immunomodulators such as methotrexate (MTX) or thiopurines as compared to monotherapy is well-established for IFX but less evident for ADL. 13, 19, 20 In principle, combination therapy has become the standard, but in practice, many patients switch to anti-TNF monotherapy after 6-12 months to prevent potential toxicity such as lymphoma. 21 This strategy, may lead to lower serum drug concentrations and an increased risk of development of anti-drug antibodies. 7 If patients on anti-TNF monotherapy lose clinical response due to immunogenicity, switching to another therapeutic agent is the most frequently used strategy. However, elimination of anti-drug antibodies appears an attractive alternative approach. Dose intensification (i.e. increasing the dosage or shorten the interval between administrations) has been proposed as a valid strategy to overcome anti-drug antibodies, but the longterm outcomes of this approach are still unclear and may be confounded by the technical inability to detect anti-drug antibodies at higher circulating drug concentrations. 22, 23 Several case series have now suggested that the addition of an immunomodulator to anti-TNF monotherapy can eliminate anti-drug antibodies and recapture clinical response in IBD patients. 24, 25 We investigated the success of this approach in a larger cohort of IBD patients treated with both IFX and ADL.
METHODS
All IBD patients treated at the Academic Medical Centre in Amsterdam in whom IFX and ADL serum concentrations had been measured between September 2005 and September 2015 were identified through an electronic database search. Serum IFX and ADL concentrations were assessed using an enzyme-linked immune sorbent assay (ELISA) by Sanquin Laboratory (Amsterdam, The Netherlands). Subsequently, patients who were found to be anti-drug antibody positive at whatever time point were selected. Anti-drug antibody levels against IFX and ADL were determined using a radioimmunoassay antigen-binding test which only detects anti-drug antibodies in the absence of drug (drug-sensitive assay).
26, 27
Patients were considered anti-drug antibody positive if levels were >12 AE/mL. The medical charts of all antidrug antibody positive patients that showed loss of clinical response to anti-TNF treatment were reviewed. Loss of response was defined as relapse of IBD-related symptoms, often confirmed by biomarker assessment, and the decision of the treating physician to change the current therapy. Anti-drug antibody positive patients were divided into four groups based on the type of interventions: (i) addition of an immunomodulator to continued IFX or ADL therapy, (ii) dose intensification of IFX or ADL regimen, (iii) cessation of anti-TNF therapy or surgery (iv) other (Table 1 ). In the second group, treatment could be intensified by either shortening the treatment interval or increasing the dose. For IFX that meant shortening the interval between infusions from every 8 weeks to every 4, 6 or 7 weeks and for ADL from every other week to weekly injections. Patients who monotherapy at the time of loss of response. In one patient who received combination therapy, thiopurine was switched to MTX which resulted in a positive clinical and serum response, indicated by a decrease in IBDrelated symptoms and an increase in anti-TNF serum concentration.
IFX vs. ADL
In seven of eight patients who received treatment with IFX, addition of an immunomodulator resulted in increased serum drug levels with a median of 2.84 lg/ mL (IQR: 1.19-4.98), which was accompanied by a decrease in anti-drug antibodies to undetectable levels after a median time of 11 months (IQR: 6-28) (Figures 1   and 2 ). In patients receiving treatment with ADL, increased serum drug concentrations were seen in six out of nine patients after addition of an immunomodulator. The median increase in ADL serum levels was 3.10 lg/mL (IQR: 1.45-4.45) (Figure 3 ). The median time for anti-drug antibody levels to become undetectable was 11 months (IQR: 2-37) ( Figure 4 ). All patients with a pharmacological response could continue their anti-TNF treatment and were in steroid free remission at 6 and 12 months of follow-up. response in 10 of 17 patients. Dose increase was performed in 6 of these 23 patients, which resulted in a favourable clinical response in two of six patients. These two patients that responded clinically, had increased serum drug levels [median drug level 3.90 lg/mL (IQR: 2.35-5.75)] which were accompanied by decreased serum anti-drug antibody levels until they were undetectable. They could continue their anti-TNF treatment and were in steroid free remission at 6 and 12 months of follow-up.
Intensification of anti-TNF therapy

DISCUSSION
Combination therapy (i.e. anti-TNF treatment combined with an immunomodulator) is associated with higher serum concentrations of monoclonal antibodies and a reduced risk of developing anti-drug antibodies. However, a considerable proportion of IBD patients are being switched to or started on anti-TNF monotherapy, which can (at least partly) be explained by the risk of adverse events associated with combination therapy. Other patients initially start with combination therapy but during the disease course, the decision is made to stop the immunomodulator because of side-effects. When these patients lose response over time, switching to another agent (within or out of class) is a commonly used approach nowadays. Optimal use of anti-TNF agents is important, since these drugs are expensive and because therapeutic options for these type of patients are often limited. An alternative approach is to maximise the TNF blocking effect by intensifying the dose, but consistent evidence to support this method is lacking. 22, 23 In patients who lose response due to anti-drug antibody formation, switching to another anti-TNF agent (within class) may appear to be the most logical approach, but this limits the available therapeutic options significantly. Therefore, a therapeutic intervention that is aimed at optimising the current anti-TNF therapy resulting in decreased anti-drug antibody levels, concomitant increased serum drug levels and, most importantly, regained clinical responses would have major clinical implications. Ben-Horin et al. described in 2013 for the first time that addition of an immunomodulator to anti-TNF therapy to regain clinical response was successful in five IBD patients with loss of response due to immunogenicity. 24 Earlier work already showed that azathioprine could induce apoptosis of T cells through inhibition of the intracellular molecule RAC-1. 28 It was demonstrated that azathioprine has the ability to delete memory T-cell clones after repeated antigen exposure. This mechanism may explain why it is possible to decrease anti-drug antibody levels by starting azathioprine due to elimination of T-cell memory responses to anti-TNF agents. Reduction in circulating anti-drug antibodies will result in higher serum anti-TNF levels, hence, more drug will be available to achieve the desired target engagement and therapeutic effect. It is currently unknown if MTX has similar effects compared to azathioprine, although the agent is a well-established antimetabolite.
Another explanation which may possibly lead to disappearance of anti-drug antibodies and a concomitant increase in serum drug levels could be the synergistic anti-inflammatory effect of immunomodulating agents. Reduced inflammation could be associated with less target (in this case tissue and circulating TNF) that needs to be blocked by anti-TNF agents.
Increased serum concentrations of monoclonal agents are often accompanied by a decrease in serum anti-drug antibody levels, but it has to be taken into account that anti-drug antibodies are frequently measured with a drug-sensitive assay. A disadvantage of this type of assay, and thereby a limitation of our study, is that anti-drug antibodies will only be detectable in the absence of drug. It is possible that anti-drug antibodies do not disappear completely, but that they are not detectable anymore in the presence of drug. To investigate this phenomenon, a prospective trial with a drug-tolerant assay should be performed.
The results of this retrospective analysis showed a median time for anti-drug antibodies to become undetectable after addition of an immunomodulator of 11 months for both IFX and ADL. However, there was a wide variation in time points between the detection of the anti-drug antibodies and the measurement of antidrug antibody levels after the intervention among patients, because the decision to order these tests was left to the discretion of the treating physician.
Nevertheless, these results show that regaining response after addition of an immunomodulator is possible, even a few months after starting an immunomodulator and this approach should be considered before stopping the current anti-TNF treatment. Anti-TNF therapy intensification could be an alternative strategy and should be considered in patients with contra-indications or intolerance to an immunomodulator.
In the majority of patients in our cohort, anti-drug antibodies were positive during multiple consecutive measurements. As a result, it is unlikely that the antidrug antibodies were transient. Combined with the knowledge that transient anti-drug antibodies are usually not associated with loss of response, this emphasises the probability of stable anti-drug antibodies in time. 29 All serum IFX concentrations in our cohort of anti-drug antibodies positive patients were trough levels, but for ADL it is difficult to retrospectively investigate at what time during the treatment interval the serum concentration was measured, since patients administer ADL at home. However, in line with recent research, the serum concentration of ADL seems to be more constant during the treatment interval compared with IFX. The route of administration (intravenously vs. s.c.) could be an explanation for this phenomenon.
Since this was a retrospective study, and thereby a limitation, prospective studies comparing thiopurines vs. MTX with different anti-TNF agents should be performed to investigate which patient will benefit from this intervention since the efficacy may vary among patients. These trials should ideally contain early, predefined antidrug antibody level measurements with a drug-tolerant assay. Clinical response should be assessed using validated scoring tools.
In conclusion, addition of MTX or thiopurines to anti-TNF therapy is an effective approach to recapture clinical response in IBD patients with loss of response to anti-TNF monotherapy due to immunogenicity. In these patients, anti-drug antibody levels decreased and serum drug levels increased in 86% and 70% of patients receiving MTX or thiopurines, respectively. This clinical strategy should be considered in IBD patients in this situation.
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